A multitargeted drug design approach offers a promising strategy in the battle against cervical cancer that simultaneously can target epsilon B-subunit of DNA polymerase, Integrin alpha-v beta-8, and Human TBK1, making it possible to disrupt multiple pro-cancer signalling pathways [6–8]. This evidence concerns the gene TBK1 and cervical cancer.